Sakaguchi Hitoshi, Ashikaga Takao, Miyazawa Masaaki, Kosaka Nanae, Ito Yuichi, Yoneyama Katsurako, Sono Sakiko, Itagaki Hiroshi, Toyoda Hidekazu, Suzuki Hiroyuki
Safety Science Research Laboratories, Kao Corporation, 2606 Akabane, Ichikai-Machi, Haga-Gun, Tochigi, Japan.
Cell Biol Toxicol. 2009 Apr;25(2):109-26. doi: 10.1007/s10565-008-9059-9. Epub 2008 Jan 19.
Recent regulations for cosmetics in Europe prohibit animal testing for evaluating the sensitization potential of chemicals to improve animal welfare. Yet, there is not an acceptable Organization for Economic Co-operation and Development non-animal skin sensitization test method. Several in vitro skin sensitization methods that focus on the activation of Langerhans cells, including human cell lines, are being evaluated as possible alternatives. In our previous study, we optimized our human cell line activation test (h-CLAT) using THP-1 cells (monocytic leukemia cell line) and conducted an inter-laboratory study. We found that measuring CD86/CD54 expression may be useful for predicting skin sensitization. The aim of this study was to confirm the relationship between CD86/CD54 expression and THP-1 cell viability in the h-CLAT. In this study, 21 allergens (e.g., dinitrochlorobenzene, p-phenylenediamine, Ni) and 8 non-allergens (e.g., SLS, lactic acid) were evaluated. For each chemical, more than 10 concentrations that gave a predicted cell viability range of 20-95% were used. The data showed that expression patterns of CD86/CD54 differed depending on chemical. For most allergens, cytotoxicity (65-90% cell viability) was needed for enhancement of CD86/CD54 expression. The criteria of "CD86 > or = 150 or CD54 > or = 200" resulted in an accuracy of 93%, which confirms appropriate cut-off criteria for h-CLAT. Furthermore, a good correlation was observed between EC3 of local lymph node assay and EC150(CD86) or EC200(CD54) of h-CLAT (12 or 16 chemicals, respectively), which would provide a useful estimate of allergic potency. These findings suggest that h-CLAT would be a good robust in vitro skin sensitization test.
欧洲近期的化妆品法规禁止进行动物试验以评估化学品的致敏潜力,从而改善动物福利。然而,目前尚无一种可接受的经济合作与发展组织非动物皮肤致敏试验方法。几种聚焦于朗格汉斯细胞激活的体外皮肤致敏方法,包括人类细胞系,正在作为可能的替代方法进行评估。在我们之前的研究中,我们使用THP-1细胞(单核细胞白血病细胞系)优化了人类细胞系激活试验(h-CLAT),并开展了一项实验室间研究。我们发现测量CD86/CD54表达可能有助于预测皮肤致敏。本研究的目的是在h-CLAT中确认CD86/CD54表达与THP-1细胞活力之间的关系。在本研究中,评估了21种过敏原(如二硝基氯苯、对苯二胺、镍)和8种非过敏原(如十二烷基硫酸钠、乳酸)。对于每种化学品,使用了超过10种浓度,其预测的细胞活力范围为20%-95%。数据表明,CD86/CD54的表达模式因化学品而异。对于大多数过敏原,需要细胞毒性(65%-90%的细胞活力)来增强CD86/CD54表达。“CD86≥150或CD54≥200”的标准准确率为93%,这证实了h-CLAT的合适截断标准。此外,局部淋巴结试验的EC3与h-CLAT的EC150(CD86)或EC200(CD54)之间观察到良好的相关性(分别为12种或16种化学品),这将有助于对过敏效力进行有效评估。这些发现表明,h-CLAT将是一种良好的稳健的体外皮肤致敏试验。